ArticleClinical, cosmetic and investigational dermatology2026
Safety and Efficacy of Mesotherapy with Placenta Polypeptide Injection for Moderate-to-Severe Sensitive Skin: A Multicenter, Randomized, Controlled Trial.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sensitive skin (SS) is a prevalent condition characterized by cutaneous hyperreactivity and neurosensory inflammation, for which effective treatments remain limited. Placenta polypeptide injection (PPI), rich in anti-inflammatory cytokines and growth factors, presents a promising therapeutic candidate. This study aimed to rigorously evaluate the safety and efficacy of mesotherapy with PPI for treating moderate-to-severe SS. Methods: In this multicenter, open-label, randomized controlled trial, 156 adults with moderate-to-severe SS were randomized (PPI group: control group = 2:1) to receive three sessions of mesotherapy with PPI (4 mL per session at 30-day intervals) or no treatment (control group) over a 90-day period. The primary endpoint was the change in total facial skin hemoglobin content, a proxy measure of cutaneous inflammation, from baseline to Day 90, quantified by a 3D skin analysis system. Safety was monitored through adverse events (AEs) and laboratory assessments. Results: A total of 154 patients were included in the full analysis set (FAS; 103 PPI group, 51 control group). At Day 90, the PPI group demonstrated a significantly greater reduction in skin hemoglobin content compared to the control group (mean change, -1705.82 ± 1808.17 vs -756.65 ± 1493.17; P=0.001). Furthermore, a significantly higher proportion of patients in the PPI group reported aesthetic improvement on the GAIS (88.9% vs 5.9% rated as "improved" to "very much improved"; P < 0.001). The incidence of AEs was comparable between the PPI (5.8%) and control (9.6%) groups (P = 0.376), with no serious AEs reported. Conclusion: Mesotherapy with placenta polypeptide injection is an effective and safe treatment for moderate-to-severe sensitive skin, leading to significant reductions in cutaneous inflammation metrics and high rates of patient-reported aesthetic improvement. Trial Registration: This study was prospectively registered at Chinese Clinical Trial Registry (No. ChiCTR2400080988, Date: 20/02/2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.